The Francis Crick Institute
Browse

Phenoscaping reveals multimodal γδ T cell cytotoxicity as a strategy to overcome cancer cell-mediated immunomodulation.

Download (9.94 MB)
journal contribution
posted on 2025-11-20, 11:26 authored by Callum Baird Nattress, Rhianna O'Sullivan, Daniel Fowler, Colin Hutton, Petra Vlckova, Jahangir Sufi, Magdalena Buschhaus, Ewa Basiarz, Maria Ramos Zapatero, Ferran Cardoso Rodriguez, Xiao Qin, Ashley Campbell, Angeliki Kanouta, Vivian SW Li, Kerry Chester, John Anderson, Marta Barisa, Jonathan PH Fisher, Christopher J Tape
γδ T cells can kill cancer cells via antibody-independent cytotoxicity (AIC) and antibody-dependent cellular cytotoxicity (ADCC). A better understanding of how these cytotoxic mechanisms are impacted by different cancer cells and different T cell donors could help identify improved immunotherapeutic strategies. To test the combinatorial interactions between T cell inter-donor heterogeneity (IDH), cancer cell inter-tumor heterogeneity (ITH), and multimodal γδ T cell killing, we performed a systematic single-cell phenoscaping analysis of >1,000 cultures of γδ T cells and colorectal cancer (CRC) patient-derived organoids (PDO). Phenoscaping analysis of post-translational modification (PTM) signaling, cell-cycle, apoptosis, and T cell immunophenotypes revealed that while unmodified γδ T cells have limited anti-tumor activity, IL-15Rα-IL-15 fusion protein (stIL15)-engineered γδ T cells can kill PDOs via AIC without exogenous cytokine support. However, when stIL15 γδ T cells only killed via AIC, cancer cells reciprocally rewired γδ T cell PTM signal networks in an ITH-specific manner to suppress anti-cancer cytotoxicity. stIL15 γδ T cells could overcome this cancer cell immunomodulation by also engaging B7-H3-targeted ADCC independent of B7-H3 checkpoint activity. Combined AIC and ADCC rescued γδ T cell PTM signaling flux and enabled γδ T cells to kill chemorefactory revival colon cancer stem cells. Together, these results demonstrate that multimodal γδ T cell cytoxicity mechanisms can overcome ITH-specific immunomodulation to kill chemorefractory cancer cells.

Funding

Cancer Research UK (CRUK) (Grant ID: C60693/A23783) Cancer Research UK (CRUK) (Grant ID: CTRQQR-2021\100004) Medical Research Council (MRC) (Grant ID: MR/T028270/1) UCLH Biomedical Research Centre (UCL) (Grant ID: BRC422) Cancer Research UK (CRUK) (Grant ID: C355/A28852) Academy of Medical Sciences (The Academy of Medical Sciences) (Grant ID: SGL024/1022) National Institute for Health and Care Research (NIHR) (Grant ID: CL-2019-18-007) University College London (UCL) (Grant ID: UTF-20-006/Fisher/UCL) Little Princess Trust (LPT) (Grant ID: CCLGA 2021 14 Fisher) Great Ormond Street Hospital Charity (GOSH) (Grant ID: VS0119) Wellcome Trust (WT) (Grant ID: 214046/Z/18/Z) Cancer Research UK (CRUK) (Grant ID: C7893/A26233) Crick (Grant ID: CC2141, Grant title: Li CC2141)

History